Current Headlines

  1. Enanta Pharmaceuticals To Present At Barclays Global Healthcare Conference
    3/3/2015

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a corporate overview on March 10, 2015 at 1:35 p.m. ET during the Barclays Global Healthcare Conference in Miami

  2. Drug Approved In Pivotal Studies Using DSG’s Fully Electronic Source Data
    3/3/2015

    DSG, Inc and Sirion Therapeutics collaborated in launching the industry’s first two pivotal Phase 3 studies using entirely electronic source data collection for the safety and efficacy of Difluprednate in the management of inflammation following ocular surgery

  3. Genedata Biologics Licensed By Pfizer Inc.
    3/3/2015

    Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Pfizer Inc. has licensed the Genedata Biologics (TM) enterprise platform for use at Pfizer biopharma research and development sites in the US and Europe

  4. Crown Bioscience Launches Life Science Product Catalog
    3/3/2015

    Crown Bioscience, Inc., a leading global drug discovery and development service company, has launched a new Life Science division specializing in in vivo and in vitro research reagents for preclinical research

  5. Frost & Sullivan Applauds Neopeutics' Commitment To Accelerating The Delivery Of New Nature-Based Pharmaceuticals And Therapeutics
    3/3/2015

    Based on its recent analysis of the enhanced drug discovery market, Frost & Sullivan recognizes Neopeutics, Inc. with the 2015 North America Frost & Sullivan Award for Technology Leadership

  6. Xadago (Safinamide) New Drug Application (NDA) Accepted For Filing By The U.S. Food And Drug Administration (FDA)
    3/2/2015

    Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, and its commercial and development partner, Zambon S.p.A., an international pharmaceutical company, announced recently that the New Drug Application (NDA) for Xadago (safinamide) has been accepted for filing by the U.S. Food and Drug Administration (FDA)

  7. Resilience And PsychoGenics Announce A Drug Discovery Partnership
    3/2/2015

    Resilience Therapeutics, Inc. (Resilience) and PGI Drug Discovery LLC (PsychoGenics), recently announced that they have entered into a partnership to discover and optimize novel treatments for Post-Traumatic Stress Disorder (PTSD) and related conditions

  8. Momenta Pharmaceuticals Announces Publication Revealing Development Of A Novel Process To Generate High-Quality Hyper-Sialylated IVIg Drug Candidate In PNAS
    3/2/2015

    Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS)

  9. Japanese Regulatory Agency Licenses Certara’s Phoenix And Simcyp Software To Support Model-Based Drug Development
    2/26/2015

    Certara, the global biosimulation technology-enabled drug development and drug safety consulting company, recently announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is equipping its pharmacometrics team with Certara’s Phoenix biosimulation solutions and its Simcyp Population-based Simulator

  10. Nodality Inc. Presents Data From Immuno-Oncology Program Applying Company’s Novel Single Cell Network Profiling (SCNP) Platform
    2/25/2015

    Nodality, Inc., which is focused on solving drug development challenges, recently announced research results from its lead immuno-oncology efforts based on applications of the Company’s Single Cell Network Profiling (SCNP) technology

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.